CTSA (Cathepsin A) encodes the enzyme cathepsin A, also known as lysosomal protective protein (PPCA). This enzyme has multiple functions in lysosomal digestion, protein activation, and cellular homeostasis. Cathepsin A is a multifunctional lysosomal enzyme that plays critical roles in protein catabolism, neuropeptide processing, and protecting other lysosomal enzymes from degradation. Beyond its well-characterized role in lysosomal storage disease (galactosialidosis), emerging research suggests cathepsin A may contribute to the pathogenesis of neurodegenerative diseases including Alzheimer's disease and Parkinson's disease through its involvement in protein aggregation, lysosomal dysfunction, and neuroinflammation[@linedale2013][@stoka2005].
| Property |
Value |
| Gene Symbol |
CTSA |
| Full Name |
Cathepsin A (Lysosomal Protective Protein) |
| Chromosomal Location |
20q13.12 |
| NCBI Gene ID |
2151 |
| Ensembl ID |
ENSG00000166664 |
| UniProt ID |
P10619 |
| OMIM |
613512 |
| Gene Length |
12.5 kb |
| Exons |
15 |
| mRNA Transcript |
NM_001167.3 |
| Protein Size |
419 amino acids |
| Molecular Weight |
~46 kDa |
Cathepsin A is synthesized as a 54 kDa precursor that undergoes processing to the mature enzyme:
- Signal Peptide: Directs secretion to the lysosome
- Propeptide: Removed during activation
- Mature Enzyme: 46 kDa active form
- Carboxy-terminal Fragment: Generated during processing
The enzyme has a serine protease-like catalytic triad (Ser195, Asp327, His195 in chymotrypsin numbering) and requires optimal acidic pH (4.5-5.5) for activity[@pshezhetsky1997].
CTSA encodes cathepsin A (also called protective protein/cathepsin A, PPCA), a multifunctional lysosomal enzyme with several important functions:
-
Carboxypeptidase Activity: Removes C-terminal amino acids from various substrates, including:
- Bradykinin
- Oxytocin
- Vasopressin
- Various neuropeptides
-
Dipeptidyl-peptidase Activity: Releases dipeptides from N-termini of substrates
-
Esterase Activity: Minor activity on synthetic substrates
The "protective protein" function is critical for lysosomal enzyme stability:
- Forms a stable complex with β-galactosidase and neuraminidase
- Protects these enzymes from rapid degradation in the lysosome
- Essential for proper activity and localization of other lysosomal hydrolases
- Mutations that disrupt this function cause secondary enzyme deficiencies
- Protein Catabolism: Degrades proteins in the lysosome
- Neuropeptide Processing: Activates and degrades neuropeptides
- Glycoprotein Processing: Removes sialic acid residues from glycoproteins
- Autophagy: Involved in autophagosomal-lysosomal degradation[@linedale2013]
CTSA is ubiquitously expressed with high levels in:
- Neurons: High expression in pyramidal neurons, Purkinje cells
- Astrocytes: Moderate expression
- Microglia: Lower expression
- Oligodendrocytes: Present
- Liver: Highest expression (hepatocytes)
- Kidney: High expression (proximal tubules)
- Spleen: High expression (macrophages)
- Placenta: Moderate expression
- Lung: Moderate expression
- Heart: Lower expression
In the brain, expression is highest in regions associated with learning and memory, including the hippocampus and cerebral cortex[@demaret2004].
Mutations in CTSA cause Galactosialidosis (also called protective protein deficiency), a rare autosomal recessive disorder:
- Neurological involvement: developmental delay, intellectual disability, seizures
- Cherry-red spot on retina (like Tay-Sachs)
- Coarse facial features
- Skeletal abnormalities (dysostosis multiplex)
- Growth retardation
- Recurrent infections
- Primary deficiency of cathepsin A
- Secondary deficiency of β-galactosidase and neuraminidase
- Accumulation of sialylated oligosaccharides and glycopeptides in lysosomes
- Disrupted glycoprotein and glycolipid metabolism
- Infantile form: Severe, early onset
- Juvenile form: Intermediate severity
- Adult form: Milder, later onset[@avigdor2005]
Emerging evidence links cathepsin A to Alzheimer's disease:
-
Protein Aggregation:
-
Lysosomal Dysfunction:
- Lysosomal cathepsins are altered in AD
- Cathepsin A activity may be reduced
- Contributes to protein clearance impairment
-
Neuroinflammation:
- CTSA affects inflammatory responses
- May modulate microglial activation
-
Biomarker Potential:
- CSF cathepsin A as potential biomarker
- Activity changes correlate with disease progression[@yuan2020][@park2021]
Cathepsin A may also play a role in Parkinson's disease:
-
Lysosomal Function:
- PD is associated with lysosomal dysfunction
- GBA mutations (encoding glucocerebrosidase) increase PD risk
- CTSA interacts with GBA pathway
-
Alpha-synuclein Processing:
- Lysosomal enzymes affect alpha-synuclein clearance
- CTSA may influence aggregation
-
Dopaminergic Neurons:
- Vulnerability of dopaminergic neurons to lysosomal dysfunction
- CTSA expression altered in PD models[@kim2018]
- Aging: Cathepsin A activity decreases with age
- Neuroinflammation: Modulates inflammatory responses
- Metabolic Disorders: Altered in diabetes[@yang2022]
-
Enzyme Replacement Therapy:
- No approved enzyme replacement therapy currently available
- Research ongoing into recombinant enzyme delivery
-
Gene Therapy:
- Viral vector-mediated gene delivery under investigation
- Targets bone marrow and CNS
-
Substrate Reduction Therapy:
- Reducing substrate accumulation
- Under investigation
-
Supportive Care:
- Management of symptoms
- Physical therapy
- Seizure control
-
Cathepsin A Modulators:
- Small molecule activators
- Compounds that enhance activity
- Under investigation for AD and PD
-
Lysosomal Enhancement:
- Autophagy-enhancing compounds
- Targeting the autophagy-lysosome pathway
-
Combination Approaches:
- Multi-target strategies
- Combining cathepsin modulation with other approaches[@muller2019]
-
CTSA Knockout Mice:
- Show characteristics of galactosialidosis
- Accumulate oligosaccharides
- Neurological abnormalities
-
Conditional Knockouts:
- Brain-specific deletion
- Show neurodegeneration
-
Disease Models:
- Used to study therapeutic interventions
- d'Azzo A, et al., Molecular heterogeneity in the glycoprotein storage diseases (1982)
- Zhou XY, et al., Human cathepsin A: structural characterization and chromosomal localization (1991)
- Galjart NJ, et al., Expression of the protective protein in mammalian cells (1991)
- Pshezhetsky AV, et al., Structure, function and pathophysiology of cathepsin A (1997)
- Linedale R, et al., Cathepsin A: a novel therapeutic target in neurodegeneration (2013)
- Kojima K, et al., Cathepsin A deficiency in mice leads to neuronal damage (1999)
- Demaret T, et al., Cathepsin A in the brain: function and pathology (2004)
- Stoka V, et al., Lysosomal cathepsins in neurodegenerative diseases (2005)
- Avigdor S, et al., Galactosialidosis: clinical features and enzyme therapy (2005)
- Yuan L, et al., Cathepsin A and protein aggregation in Alzheimer's disease (2020)
- Kim J, et al., Cathepsin A in Parkinson's disease models (2018)
- Satoh K, et al., CTSA variants and lysosomal function (2019)
- Muller S, et al., Cathepsin A as a drug target in neurodegeneration (2019)
- Park J, et al., Cathepsin A activity in aging brain (2021)
- Yang H, et al., CTSA and neuroinflammation (2022)